BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR
Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor blocking KRAS independent of mutation type, and MRTX849, a KRAS G12C selective inhibitor in patients with solid tumors that harbor the KRAS G12C mutation. The collaboration will investigate the potential of this combination to provide more effective and durable responses for patients with lung and colorectal cancers who currently have limited treatment options.
Preclinical data suggest that the combination of a KRAS G12C inhibitor with a SOS1::pan-KRAS inhibitor results in increased anti-tumor activity based on the complementary mechanisms of these targeted oncology agents. By shifting the equilibrium from active KRAS(ON) towards the inactive KRAS(OFF) form, SOS1::pan-KRAS inhibitors have the potential to sensitize KRAS G12C mutant tumors to covalent KRAS G12C inhibitors that bind to KRAS(OFF).
“We look forward to collaborating with Boehringer Ingelheim to test this combination in clinical trials,” said Joseph Leveque, M.D., Executive Vice President and Chief Medical Officer of Mirati Therapeutics, Inc. “This collaboration is aligned with the broad and aggressive development strategy we have for MRTX849 and brings the potential for another therapeutic option to patients with KRAS G12C mutations.”
“We are excited to partner with Mirati in our ambition to make a difference for people living with KRAS-driven cancers. Combining our SOS1::pan-KRAS inhibitor with the mutation specific G12C inhibitor could be a win-win approach enhancing the response to therapy,” said Victoria Zazulina, M.D., Global Medical Head for Oncology at Boehringer Ingelheim. “We have a comprehensive KRAS program including the first SOS1::pan-KRAS inhibitor in the clinic, BI 1701963, for which we are exploring several combinations to optimize its therapeutic benefit in broad patient populations.”
Under the terms of the non-exclusive collaboration, Mirati will be the sponsor of the trial and Boehringer Ingelheim and Mirati will jointly share the costs of and oversee clinical development for the combined therapy.
MRTX849 is an investigational, orally available small molecule that is designed to potently and selectively inhibit a form of KRAS, which harbors a substitution mutation (G12C). KRAS G12C mutations are present in approximately 14% of non-small cell lung cancer (NSCLC) adenocarcinoma patients, in 3-4% of colorectal cancer patients, and in subsets of other types of cancer. Tumors characterized by KRAS G12C mutations are commonly associated with poor prognosis and resistance to therapy, and patients with these mutations have few treatment options. MRTX849 is being evaluated in a Phase 1/2 trial treating patients with molecularly identified, KRAS G12C-positive advanced solid tumors and in the first quarter of 2020, enrollment began in the registration enabling cohort in monotherapy NSCLC, colorectal cancer and pancreatic cancer.
About BI 1701963
BI 1701963 is an investigational, orally available small molecule, that is designed to bind to the catalytic domain of SOS1 preventing the interaction with KRAS(OFF) and simultaneously blocking SOS1 driven feedback. This reduces the formation of KRAS(ON) and in consequence inhibits MAPK pathway signaling in KRAS-dependent cancers. The selective inhibition of SOS1 is a therapeutic concept that could allow KRAS blockade irrespective of KRAS mutation type (pan-KRAS approach). SOS1::KRAS inhibitors exhibit activity on a broad spectrum of KRAS alleles, including all major G12D/V/C and G13D oncoproteins, as recently published by Hofmann MH, et al. in Cancer Discovery, a journal of the American Association of Cancer Research (AACR). BI 1701963 is currently being evaluated in a Phase I clinical trial in patients with advanced KRAS-mutated cancers to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties, and preliminary efficacy of BI 1701963 alone and in combination with MEK inhibitors.
Forward Looking Statements
This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. (“Mirati”). Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati’s drug development pipeline, including without limitation MRTX849, sitravatinib and MRTX1133, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.
Mirati’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati’s programs are described in additional detail in Mirati’s quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the U.S. Securities and Exchange Commission (the “SEC”) available at the SEC’s Internet site (www.sec.gov).These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Boehringer Ingelheim’s Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Please click on the following link for ‘Notes to Editors’:
Investor Relations and Media Contacts:
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
Junior Product Communications Manager
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-183874
Mirati Therapeutics, Inc.
Mirati Therapeutics Inc.
Director, Investor Relations & Corporate Communications
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bentley Systems Announces Winners of Year in Infrastructure 2020 Awards21.10.2020 20:30:00 CEST | Press release
Bentley Systems, Incorporated, (Nasdaq: BSY), the infrastructure engineering software company, has announced the winners of the Year in Infrastructure 2020 Awards. The annual awards program honors the extraordinary work of Bentley users advancing design, construction, and operations of infrastructure throughout the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005893/en/ All Year in Infrastructure 2020 Award winners, finalists, and nominees will be featured in the 2020 Infrastructure Yearbook, which will be published in early 2021. (Photo: Business Wire) Sixteen independent jury panels selected the 57 finalists from over 400 nominations submitted by more than 330 organizations from more than 60 countries. Bentley Systems acknowledged 19 Year in Infrastructure 2020 Awards winners and 14 Special Recognition awardees on October 21 during the Year in Infrastructure 2020 Conference, held virtually for the first time
Saudi Arabia Sets out Strategy to Become a World Leader in Artificial Intelligence By 203021.10.2020 18:07:00 CEST | Press release
Saudi Arabia revealed its National Strategy for Data & AI (NSDAI) which will make the country a global leader in Artificial Intelligence by 2030. Saudi Arabia’s NSDAI intends to put AI at the heart of the country’s development and growth. By 2030, Saudi Arabia’s vision is to become the place where the best of Data and AI is made reality. Under the strategy, Saudi Arabia will implement a multi-phase, multi-faceted plan that includes skills, policy and regulation, investment, research and innovation, and ecosystem development. This will enable the country to become a global hub for data and AI, and to rank among the top data-driven economies in the world. Speaking at the launch of the strategy, HE Dr. Abdullah Bin Sharaf Alghamdi, President of SDAIA, said: “The National Strategy for Data and AI sets the direction and foundations upon which we will unlock the potential of data and AI to fulfill our national transformation priorities and establish Saudi Arabia as a global hub for data and
Women 20 (W20) Challenges G20 Leaders to Close the Gap Between Imagination and Reality on Women’s Equality21.10.2020 18:01:00 CEST | Press release
Women 20 (W20), the women’s engagement group to the G20, challenged G20 leaders to live up to their promises of the past and make women’s economic equality a reality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005766/en/ W20 Chair Dr. Thoraya Al Obaid and G20 Chair of Trade and Investment His Excellency Dr. Majid Alqassabi with the final Communiqué of the W20 Working Group (Photo: AETOSWire) Laying out measures to expedite the economic recovery from the COVID-19 pandemic, the W20 presented its Communiqué to H.E. Dr. Majid Alqassabi, Minister of Commerce, Chair of G20 Trade and Investment, representing the Presidency of the G20. The pandemic provides an opportunity for G20 leaders to reset G20 economies based on the full and equitable participation of women. “Unless urgent action is taken, the pandemic will continue to exacerbate gender inequalities, expose vulnerabilities, and roll back gains made on women’s equali
Saudi Arabia Partners With the World Bank to Ensure No Nation Is Left Behind on AI21.10.2020 17:59:00 CEST | Press release
The World Bank and Saudi Arabia have announced a long-term partnership to accelerate the use of Artificial Intelligence (AI) in developing nations in support of economic and development goals. The objective is to ensure that no nation is left behind in the race to unlock the value of AI while ensuring the appropriate safeguards are in place to manage the risks associated with AI. Under the partnership, the World Bank and Saudi Arabia, represented by the Saudi Data and Artificial Intelligence Authority (SDAIA), will cooperate to assist countries in creating policies and initiatives that harness the power of AI to support national development and growth. AI and related technologies are expected to unlock an additional $15tn of economic value worldwide before 2030, but many developing nations do not have yet the technical readiness to share in this new wealth. The partnership will support target nations to identify gaps in their own readiness and ability to utilize AI and data and develop
Taulia Appoints Andy Lee as Director, Supply Chain Finance21.10.2020 16:30:00 CEST | Press release
Taulia, the leader in working capital technology solutions, has today announced the appointment of Andy Lee as Director, Supply Chain Finance. Based in New York, Lee will be responsible for expanding Taulia's funding partners, building strategic relationships and supporting product development in North America. “The natural next step for our growing team was to bring someone onboard with deep experience within the banking sector and superior knowledge of the fintech space. Andy will enable us to develop the right financial partnerships so that we can continue to offer a disruptive and valuable service to our customers,” says Alexander Mutter, Managing Director of Capital Markets, Taulia. “In these unprecedented times, supply chain finance has been a key source of working capital for businesses large and small. I’m looking forward to diving right in, driving strategic relationships and building connections with our North American partners that will help expand access to these solutions,
Eaton Launches New Metal 3D Printing Program to Reduce Development Time, Improve Efficiency21.10.2020 16:00:00 CEST | Press release
Power management company Eaton today announced its Vehicle Group is implementing a new 3D metal printing program as a part of its Industry 4.0 strategy to reduce development time and improve efficiency. The first metal printer system was installed at the Kings Mountain, N.C., facility, and a global deployment of 3D polymer printing technology is slated to be completed by first-quarter 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005571/en/ Eaton’s Vehicle Group reduced cost and development time using its 3D metal printing capabilities to produce this oil fill nozzle. (Photo: Business Wire) The 3D printers are being utilized to create high-quality fixtures, safety devices, automation grippers for assembly and handling, and maintenance components requiring replacement. Prototype development is following the same strategy to support faster product development trials and improve efficiency. Improving output and eff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom